News and Announcements
Imugene Ltd (ASX: IMU) Seeking Capital for HER-Vaxx
- Published November 21, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Imugene Ltd (ASX: IMU) is raising capital for further immuno-oncology clinical testing
- HER-Vaxx, an anti-cancer vaccine therapy, has been utilised in initial clinical testing on patients with gastric cancer.
- The ASX has granted a halt on trade allowing the company to prepare.
Imugene Ltd (ASX: IMU), a clinical-stage immuno-oncology company treating gastric, breast, ovarian, lung & pancreatic cancers, has arranged a halt on trade approved by the Australian Stock Exchange.
This halt comes about as a result of the company’s desire to raise capital. The halt will allow Imguene to have sufficient preparation time.
HER-Vaxx, the leading Imugene product that capitalises on the body’s ability to create antibodies against disease, has commenced clinical testing on gastric cancer patients.
Two leading antibody medications apply the same method as HER-Vaxx employs, utilising the same receptor. These alternative products possessing annual sales of US $8.2 billion.
About Imugene Ltd (ASX: IMU)
Imugene is a clinical stage immuno-oncology company. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets. HER-Vaxx is an immuno-oncology therapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
